MedTrace Logo

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

NCT00841971 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2014-12-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of anidulafungin versus fluconazole for the prevention of fungal diseases in liver transplant recipients

Conditions

  • Mycoses
  • Fungemia
  • Central Nervous System Fungal Infections
  • Lung Diseases, Fungal

Interventions

DRUG

Anidulafungin

200 mg IV loading dose followed by 100 mg qd for 21 days

DRUG

Fluconazole

400 mg IV for 21 days

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Nina Singh, MD · University of Pittaburgh, VA Pittsburgh Health Systems

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-07-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841971 on ClinicalTrials.gov